Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a compound in strawberries help aging lungs?

NCT ID NCT07676435

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests whether fisetin, a natural compound found in fruits and vegetables, can improve lung function in older adults. Researchers will give fisetin or a placebo to 40 people aged 60 and older, including both former smokers and never-smokers. The goal is to see if fisetin can clear aging cells from the lungs and help people breathe better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fisetin
What this could lead to
If it works, this could point toward a treatment to slow or reverse age-related lung decline, potentially improving breathing and quality of life in older adults.
What could go wrong
This is a small, early-phase pilot study with only 40 participants. The results may not apply to everyone, and fisetin's long-term effects on lung function are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 60 years and older who are physically capable of participating in study procedures; * Willing to be randomized to fisetin or placebo; weight stable within the previous 2 months (\<5-pound change); * No blood donation within 2 months before screening; absence of unstable chronic disease; * Willing to maintain baseline activity level throughout the study; * Body mass index \<30 kg/m²; * Either a history of at least 10 pack-years of cigarette smoking or never-smoking status. Exclusion Criteria: * Electrocardiogram (ECG) abnormalities, including prolonged QTc. * Use of fisetin, other flavonoid supplements, or known senolytic compounds within 6 months prior to screening. * Resting systolic blood pressure \>160 mmHg or diastolic blood pressure \>110 mmHg. * Known allergy or hypersensitivity to fisetin or any component of the study product. * Active malignancy, except non-melanoma skin cancer. * Clinically significant hepatic, renal, cardiovascular, endocrine, immunologic, metabolic, or other uncontrolled medical conditions that, in the opinion of the investigator, would interfere with study participation or interpretation of results. * Clinically significant laboratory abnormalities, including severe anemia, leukopenia, thrombocytopenia, uncontrolled diabetes, advanced kidney disease, significant liver dysfunction, or evidence of systemic inflammation. * Human immunodeficiency virus (HIV) infection, active hepatitis B or hepatitis C infection, or invasive fungal infection. * History of diverticulitis or diverticulosis with gastrointestinal bleeding. * Current use of systemic corticosteroids. * Current use of warfarin. * Current use of medications with significant interaction potential with fisetin, including selected CYP450 or transporter substrates, inhibitors, or inducers, unless such medications can be safely withheld according to protocol requirements. * Recent medication, supplement, or lifestyle changes that may affect study outcomes, in the opinion of the investigator. * Inability to perform required study procedures, including pulmonary function testing, exercise testing, or other protocol assessments. * Unwillingness or inability to provide informed consent. * Pregnancy or breastfeeding. * Any other condition that, in the opinion of the investigator, would make participation unsafe or compromise study integrity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related lung function decline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Smoking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cedars-Sinai Medical Center

    RECRUITING

    Los Angeles, California, 90048, United States